MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Adaptive Biotechnologies Corp

Gesloten

7.94 6.15

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

7.28

Max

8.03

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.6M

-34M

Verkoop

1M

47M

EPS

-0.228

Winstmarge

-71.044

Werknemers

619

EBITDA

-1.8M

-26M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+27.26% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-56M

1.1B

Vorige openingsprijs

1.79

Vorige sluitingsprijs

7.94

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Adaptive Biotechnologies Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 apr 2025, 23:55 UTC

Populaire aandelen

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 apr 2025, 22:50 UTC

Belangrijke Marktbewegers

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 apr 2025, 21:08 UTC

Winsten

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 apr 2025, 21:00 UTC

Winsten

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 apr 2025, 23:56 UTC

Marktinformatie

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 apr 2025, 23:44 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 apr 2025, 23:44 UTC

Marktinformatie

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 apr 2025, 23:44 UTC

Top Nieuws

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 apr 2025, 23:32 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 23:32 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 23:32 UTC

Marktinformatie

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 apr 2025, 23:12 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 apr 2025, 23:12 UTC

Marktinformatie

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 apr 2025, 23:10 UTC

Marktinformatie

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 apr 2025, 23:09 UTC

Marktinformatie

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 apr 2025, 23:09 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:57 UTC

Marktinformatie

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 apr 2025, 22:56 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:56 UTC

Marktinformatie

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 apr 2025, 22:43 UTC

Top Nieuws
Acquisities, Fusies, Overnames

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 apr 2025, 22:12 UTC

Marktinformatie

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 apr 2025, 21:48 UTC

Top Nieuws

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 apr 2025, 21:41 UTC

Marktinformatie

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 apr 2025, 21:17 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 21:17 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 21:17 UTC

Marktinformatie

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 apr 2025, 21:04 UTC

Top Nieuws

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 apr 2025, 21:03 UTC

Marktinformatie

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 apr 2025, 20:53 UTC

Winsten

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 apr 2025, 20:52 UTC

Winsten

Kaiser Aluminum Changes Inventory Acctg Methodology

Peer Vergelijking

Prijswijziging

Adaptive Biotechnologies Corp Prognose

Koersdoel

By TipRanks

27.26% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.57 USD  27.26%

Hoogste 12 USD

Laagste 7 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Adaptive Biotechnologies Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

7 ratings

6

Buy

1

Hold

0

Sell

Technische score

By Trading Central

7.1126 / 7.67Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.